Forsta AP Fonden bought a new stake in Clarivate Plc (NYSE:CLVT – Get Rating) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,000 shares of the company’s stock, valued at approximately $139,000.
Other institutional investors have also recently bought and sold shares of the company. Fiera Capital Corp grew its holdings in shares of Clarivate by 19.1% during the 2nd quarter. Fiera Capital Corp now owns 60,660 shares of the company’s stock valued at $841,000 after purchasing an additional 9,728 shares during the last quarter. Clarkston Capital Partners LLC increased its holdings in shares of Clarivate by 67.2% during the second quarter. Clarkston Capital Partners LLC now owns 18,155,475 shares of the company’s stock worth $251,635,000 after buying an additional 7,295,534 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Clarivate by 26.7% in the 2nd quarter. Principal Financial Group Inc. now owns 57,290 shares of the company’s stock valued at $794,000 after acquiring an additional 12,079 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of Clarivate by 2.4% during the 2nd quarter. Cerity Partners LLC now owns 64,562 shares of the company’s stock valued at $895,000 after acquiring an additional 1,531 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp grew its position in Clarivate by 7.4% during the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 173,636 shares of the company’s stock worth $2,407,000 after acquiring an additional 12,033 shares during the last quarter. Institutional investors and hedge funds own 83.42% of the company’s stock.
Insider Activity at Clarivate
In other Clarivate news, Director Andrew Miles Snyder purchased 208,333 shares of the firm’s stock in a transaction on Wednesday, September 14th. The stock was purchased at an average cost of $11.61 per share, for a total transaction of $2,418,746.13. Following the acquisition, the director now owns 208,333 shares in the company, valued at approximately $2,418,746.13. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider James Gordon Samson sold 100,000 shares of Clarivate stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $10.48, for a total value of $1,048,000.00. Following the completion of the sale, the insider now owns 737,898 shares in the company, valued at approximately $7,733,171.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Andrew Miles Snyder bought 208,333 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were bought at an average price of $11.61 per share, for a total transaction of $2,418,746.13. Following the transaction, the director now directly owns 208,333 shares in the company, valued at $2,418,746.13. The disclosure for this purchase can be found here. 24.88% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Clarivate Trading Up 0.9 %
NYSE:CLVT opened at $9.34 on Tuesday. Clarivate Plc has a 52 week low of $8.00 and a 52 week high of $25.63. The firm’s fifty day moving average is $9.90 and its 200-day moving average is $12.34. The firm has a market cap of $6.30 billion, a P/E ratio of -1.37 and a beta of 0.98. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.89 and a current ratio of 0.89.
Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs.
- Get a free copy of the StockNews.com research report on Clarivate (CLVT)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.